Vermillion Performs 3,920 OVA1 Tests in Q2, But Revenues Fall 9 Percent on Drop in Licensing Income

The quarter's OVA1 sales numbers exceeded Vermillion's guidance of between 3,200 and 3,500 tests and the company predicted that sales would continue to accelerate, offering a guidance of between 4,000 and 4,300 tests for Q3. Concerns about costs and potential competitors loom, however.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.